NEOD001: Additional Phase I/II data

Data from 27 patients with AL amyloidosis and persistent organ dysfunction in an open-label, dose-escalation, U.S. Phase I/II trial showed that the recommended Phase II dose of IV NEOD001 was 24 mg/kg...